

PATHFINDER


August 7, 2012

Steven D. Singleton
Limestone Fund, LLC
1600 Division Street, Suite 580
Nashville, TN 37203

Dear Mr. Singleton:

Pursuant to Subordinated Convertible Promissory Note entered into as of April 25, 2012 and Pursuant to Series B2 Preferred Stock and Warrant Purchase Agreement entered into as of May 4, 2012, by and between Limestone Fund, LLC and Pathfinder Therapeutics, Inc., a Delaware Corporation, Limestone Fund, LLC, has purchased a note convertible into Series B2 Preferred Stock of Pathfinder Therapeutics, Inc. for \$50,000 and Series B2 Preferred Stock for \$150,000, respectively.

Thank you,

A large, stylized handwritten signature in black ink, appearing to read 'Jim Cloar', is written over the typed name and title.

Jim Cloar
Pathfinder President/CEO